India Broadband Forum

Guest

Eastman Kodak Company’s Molecular Imaging Systems group announced the release of the KODAK In-Vivo Multispectral system for advanced research applications. The system is capable of identifying molecular abnormalities that are the origin of disease at a very early stage, which can lead to expedited development of effective therapeutics. In vivo molecular imaging allows non-invasive measurement of biological processes within a living organism. The new system incorporates workflow automation and advanced multispectral fluorescence, luminescence, digital x-ray and radioisotopic imaging capabilities for in vivo imaging of small animals for drug development and life science research.

The In-Vivo Multispectral system’s computer controlled multispectral tuning of excitation light provides greatly enhanced sensitivity allowing for the identification and separation of multiple fluorochromes and the removal of autofluorescence background. The In-Vivo Multispectral system automatically generates and analyzes multispectral fluorochrome images with spatially co-registered x-ray and white light images for improved localization of biological markers in vivo. A wide range of excitation wavelengths, from optical through near-infrared, enable researchers to optimize imaging of a wide range of fluorochromes and biomarkers.

“By combining multispectral fluorescence with digital x-ray, the system’s highly improved sensitivity allows researchers to precisely locate, identify and monitor changes in molecular activity of specific cells or organs within small animals, long before morphological changes can be detected,” said Shahram Hejazi, Worldwide General Manager of Molecular Imaging Systems. “As a result, our customers can gain a better understanding of very early disease states which could expedite the development of therapeutic pathways that can help lead to a cure for a specific disease.”